Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.
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Introduction
Burkitt lymphoma (BL) is a rare and highly aggressive lymphoid neoplasm derived from germinal centre B--cells. It accounts for approximately 1--2% of adult lymphomas in Western countries, and a total of 20--25 cases are seen in Sweden and Denmark (cumulative population: 25 mio) every year.
The genetic hallmark of BL is the MYC translocation, which induces a highly proliferative state within the cells carrying the translocation [1] . There are three main subtypes of BL: sporadic, endemic and HIV--associated. The endemic variety is associated with Epstein Barr virus and malaria, and affects children in the equatorial region, whereas the sporadic subtype is the most frequently occurring in Western countries. A recent study of the Swedish Lymphoma Registry (SLR) confirmed advanced age, poor WHO performance status (PS) and elevated serum lactate dehydrogenase (S--LDH) as significant prognostic factors for adult BL [2] .
Due to the rapid tumour growth, a prompt diagnosis and start of appropriate treatment are crucial in order to optimize outcome in BL [3] . The optimal standard treatment for adult BL is not yet entirely defined due to the rarity of the disorder and the consequent lack of prospective randomized trials. Hence, adults diagnosed with BL are exposed to a range of different chemotherapy regimens, according to a variety of different local therapeutic guidelines [4] . This may in turn result in variable outcomes. An evidence--based standardised treatment protocol for adult BL would therefore be highly desirable.
A number of studies have shown that adapted paediatric protocols consisting of multiple agents given within short and intensive schedules, including fractionated alkylating agents and CNS-prophylaxis with high--dose methotrexate with or without high--dose cytarabine, are effective also in the adult BL population, with long--term survival rates up to 90% [3, 5--10] . Most of these paediatric protocols were introduced among the treatment options of adult sporadic BL in the beginning of the 1990s [11] . However, due to advanced age or co--morbidity, a substantial number of patients do not tolerate intensive therapy and end up receiving less intensive regimens , such as cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) [12, 13] . This is particularly unfavourable, since elderly patients also tend to present more often with disseminated disease [3] .
The most frequently used regimens based on paediatric protocols are CODOX--M/IVAC (cyclophosphamide, doxorubicin, vincristine, methotrexate, etoposide, ifosfamide and cytarabine), the German BFM (Berlin--Frankfurt--Munster, vincristine, ifosfamide, methotrexate, cytarabine, etoposide, cyclophosphamide, doxorubicin, betamethasone), and the French Lymphome Malins B (LMB) regimens. These have all shown rates of overall survival (OS) among adult BL patients similar to those achieved in the paediatric setting [7, 14--16] . The BFM regimen, as modified by the German Adult Acute Lymphoblastic Leukaemia (GMALL) group, demonstrated a 2--year OS of 82% in HIV negative BL patients [17] . The CODOX--M/IVAC regimen has been reported to be associated with 2--
year OS--rates of 64--82% [3, 18] . In general, reported data indicate that intensive regimens are substantially more effective than CHOP in adult sporadic BL [6, 11, 13] . Other regimens used for BL include the Cancer and Leukemia Group B (CALGB) 9251 regimen [19] , and the dose--adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (DA--EPOCH) [20] .
For several other B--cell lymphoma subtypes, addition of the anti--CD20 monoclonal antibody rituximab to chemotherapy has been shown to improve outcome. A few studies have reported a positive effect of rituximab given in combination with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (Hyper CVAD) in patients with adult sporadic BL [21, 22] . Similar observations were reported for the combination of rituximab with CODOX--M/IVAC [23--25] . In Sweden and Denmark, the same protocols have been utilized since 2000 except for Hyper--CVAD, which was introduced in Sweden in 2005. Rituximab has been increasingly adopted for the treatment of in CD20--positive malignancies in this region since 2003--2004.
The aims of the present study were to determine the efficacy of different chemotherapy regimens in a population based series of adult BL patients in Sweden and Denmark, including the impact of rituximab addition, and to evaluate whether outcome has improved within the study observation period (2000--2009 ).
Patients and methods
This is a collaborative study within the Nordic Lymphoma Group framework, based on collaboration between the Swedish and Danish Lymphoma Groups and their respective population--based registries. As previously described, the Swedish Lymphoma Registry (SLR) was established in 2000 by the Swedish Lymphoma Group, to expand the data already included in the Swedish Cancer Registry [26] . Data from the SLR are presented in annual reports (www.swedishlymphoma.se) and cover approximately 95--97% of all lymphoma cases diagnosed in Sweden.
As previously reported the lymphoma registry of the Danish Lymphoma Group was initiated in 1983 covering western Denmark (Jutland and Funen) and was extended in 1999 to include all patients with lymphoma in Denmark. It also issues annual reports (www.lymphoma.dk) and coverage is cross--checked against the Central Danish Cancer Registry as well as the Danish Central Registry of Pathology [27] .
The study population in the present series includes all adult patients diagnosed with BL from January 
Statistical methods
For estimation of OS rates, the Kaplan--Meier method was used. When comparing survival curves the log--rank test was utilized. Hazard ratios (HR) for the various variables were calculated at both 
Results

Patient characteristics
A total of 258 patients were diagnosed between January 1, 2000 and December 31, 2009. Of these, a total of 122 (47 %) patients died. The median follow--up for surviving patients was 58 months. The median age was 56 years (range: 15--93 years). There was a male to female ratio of 2 
Prognostic factors
As shown in Table 1 , high age was the only parameter associated with impaired OS at both univariate and multivariate level. When stratifying into three age groups: <40 years, 40--65 years and >65 years, the estimated two--year OS in the three groups was 86%, 65% and 23%, respectively.
Poor performance status, elevated S--LDH, presence of B--symptoms, and bone marrow involvement were all associated with inferior survival at univariate level, but did not retain prognostic value in the multivariate analysis. CNS involvement, in all cases leptomeningeal, was not significantly associated with outcome. Gender, Ann Arbor stage, number of extranodal sites and the presence of bulky disease (>10 cm) had no significant prognostic impact (data not shown).
Chemotherapy regimens
Treatment--related data were available in 205 patients (79.5%). The distribution of chemotherapy regimens overall and among specific patient subsets is summarized in Table 2 Overall survival 2--year OS estimates related to prognostic factors and chemotherapy regimens are shown in Table 2 and Figure 1 . The high--intensive regimens BFM, Hyper--CVAD and CODOX--M/IVAC were all significantly superior to the low--intensive CHOP/CHOEP regimen after correcting for age and use of rituximab (HR=2.0 95% C. I.:1.0--4.1, p=0.04). To enable us to detect a potential difference in efficacy among the BFM, Hyper--CVAD and CODOX--M/IVAC regimens, an additional multivariate analysis was performed restricted for patients receiving these regimens, correcting for age and rituximab, but no significant difference between the individual regimens could be detected (Table 3) frequently with a poor pre--therapeutic PS. In patients receiving intensive regimens, there were more patients presenting with poor performance status (>1) in the earlier time period (38%), compared to 18% in the later period (p=0.01). For patients with missing treatment data, there was no difference in survival between the two time periods, 2--year OS 35.6% vs. 40.0%.
Rituximab
Information regarding the use of rituximab was available for 163 out of the 205 patients for whom chemotherapy data was available. Of the 163 patients, 111 (68%) received rituximab and 52 (32%) did not. Rituximab was mainly used from 2005 and onwards. In the univariate analysis, the addition of rituximab was associated with improved OS (HR=0.57, 95% C. I.:0.34--0.94, p=0.03). When stratifying the study population into three age groups, the favourable effect of rituximab on outcome was restricted to the cohort aged 40--65 (HR=0.46, 95% C.I.:0.21--0.98, p=0.047).
However, when adjusting for age and chemotherapy regimen the addition of rituximab failed to sustain significance ( Table 1) 
Discussion
It is of importance to establish an effective standard treatment for adult BL, due to the aggressive nature of this disease and its high curability when properly treated. The two aims of this study were to evaluate and compare, in a population--based patient cohort, standard treatments for adult BL and to establish whether outcome among BL patients had improved over the 10--year time frame of this study (2000--2009 ). We found an improvement in OS over the observation period of this study among younger patients (up to 65 years), but not among elderly ones (>65 years). The median age of our study population was 56 years, higher than previously reported [7, 12] , which likely reflects the population based nature of the cohort. In terms of outcome prediction, advanced age was the only prognostic factor that retained independent prognostic value at both uni--and multivariate level.
Surprisingly, CNS involvement did not prove a significant indicator of prognosis and 45% of patients exhibiting CNS involvement in this study were found to survive long--term, indicating that the CNS directed drugs, i e high dose methotrexate and cytarabine, incorporated in the high--intensive chemotherapy regimens are sufficient to eradicate CNS disease.
As expected, patients who received no treatment exhibited a very short survival time (<1 year). Their median age was 81 years, and they also more often presented with poor PS and elevated LDH. The low--intensive CHOP/CHOEP regimens achieved a 2--year OS of 38.8%, confirming that CHOP or CHOP-like regimens are inadequate for the treatment of BL [3] . Surprisingly, OS was better for patients treated with CHOP/CHOEP in the period 2000--2004 compared to those treated with the same regimen in the later 5--year period (2005--2009 ). This is likely to reflect a higher median age and a higher frequency of patients with poor PS in the latter group, indicating that more patients today receive high--intensive regimens. The outcome advances achieved within the last decade appear to have primarily benefited the younger and middle aged patient population. This highlights the need to develop regimens especially suited for patients of advanced age, such as the DA--EPOCH--R [28] and the modified B--ALL/NHL2002 [17] schedules. The 2--year OS of patients who received CODOX--M/IVAC was estimated at 69% in this series. The CODOX--M/IVAC (Magrath) regimen is widely used globally and has been studied in a number of retrospective studies, with similar outcome in terms of OS as in our study [14, 23--25] . The pattern of survival after CODOX--M/IVAC regimen was somewhat different than for BFM and Hyper--CVAD since 4 of 27 patients alive one year after diagnosis subsequently developed relapse and died, 3 of the 4 without rituximab initially. As this relapse pattern is unusual with BL, it cannot be ruled out that these patients may have been misdiagnosed.
In this series, the BFM and Hyper--CVAD regimens were associated with the highest 2--year OS rates, 82% and 83% respectively.
Whether the addition of rituximab to the treatment regimens contributed to the OS improvement observed in younger patients (≤65) during the later time period, cannot be conclusively clarified by the present retrospective study. Rituximab was associated with a statistically significant improvement in OS at univariate level. However, this significance disappeared when correcting for age and use of chemotherapy regimen. In addition, missing information of treatment and rituximab was mainly present in the earlier time--period and this may also contribute to lack of significance in the multivariate analysis. OS was only marginally improved by the addition of the antibody in patients who received BFM or CHOP/CHOEP. For patients treated with CODOX--M/IVAC the improvement was more evident, although not statistically significant, in line with recent retrospective series [23--25] , as well as one prospective report [29] , where the addition of rituximab to CODOX--M/IVAC was found to improve OS compared with historical controls. Similarly, a number of retrospective trials have evaluated the effect of adding rituximab to Hyper--CVAD and have found it beneficial compared to Hyper--CVAD alone [11, 21, 22] . In the present series, all patients treated with Hyper--CVAD had also received rituximab, precluding us from making this comparison. In patients treated with BFM, similar two--year OS rates of over 80% were achieved irrespectively of rituximab addition. Thus, the effect of rituximab addition in BL treatment cannot be determined in this study, and the potential impact of this agent in BL treatment warrants further investigation.
A limitation in a population based study, such as this, is the lack of central pathology review. This study is likely to contain cases that would not be classified as true BL cases according to the current WHO criteria even though uniform diagnostic criteria have been applied. Particularly in the cohort aged over 40 years a proportion of patients included in this study would now likely be classified as B-cell lymphoma intermediate between BL and DLBCL. However, there are data suggesting that patients diagnosed with lymphomas with such characteristics may benefit from the same short, high--intensive multiagent protocols as used when treating BL [23, 29] .
In the absence of randomized trials, population--based data, such as those presented in this study, are among the few sources of evidence that can contribute to the establishment of rational treatment recommendations for non HIV--associated adult BL. Based upon population--based data from Sweden and Denmark , we can conclude that patients with adult BL should optimally receive intensive chemotherapy regimens, and that outcome among younger adult BL patients (≤ 65 years) has improved over the last decade. However, novel treatment strategies are needed for elderly BL patients.
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